PPAR-α activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 6, 2006, Pages

  Zhao, Xueying ^a   Quigley, Jeffrey E ^a   Yuan, Jianghe ^a   Wang, Mong Heng ^a   Zhou, Yiqing ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cytochrome P 450; Kidney; Metabolic syndrome; Peroxisome proliferator activated receptor ; Renal vessels

Indexed keywords

6 (2 PROPARGYLOXYPHENYL)HEXANOID ACID; ACETYLCHOLINE; CHOLESTEROL; CYTOCHROME P450 2C; CYTOCHROME P450 2C11; CYTOCHROME P450 2C23; CYTOCHROME P450 4A; FENOFIBRATE; HEXANOIC ACID DERIVATIVE; ICOSANOID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; INSULIN BLOOD LEVEL; KIDNEY CORTEX; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WEIGHT GAIN;

ANIMALS; ANTILIPEMIC AGENTS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENDOTHELIUM, VASCULAR; IMMUNOBLOTTING; INSULIN; ISOENZYMES; KIDNEY; KIDNEY CORTEX; LIPIDS; MALE; MICROCIRCULATION; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PPAR ALPHA; PROCETOFEN; RATS; RATS, ZUCKER; RENAL CIRCULATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASODILATION; WEIGHT GAIN;

EID: 33744940507     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00937.2005     Document Type: Article

References (50)

1. Adeagbo AS, Joshua IG, Falkner C, and Matheson PJ. Tempol, an antioxidant, restores endothelium-derived hyperpolarizing factor-mediated vasodilation during hypertension. Eur J Pharmacol 481: 91-100, 2003.
2. Bonetti PO, Lerman LO, and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175, 2003.
3. Bussemaker E, Popp R, Fisslthaler B, Larson CM, Fleming I, Busse R, and Brandes RP. Aged spontaneously hypertensive rats exhibit a selective loss of EDHF-mediated relaxation in the renal artery. Hypertension 42: 562-568, 2003.
4. Capell WH, DeSouza CA, Poirier P, Bell ML, Stauffer BL, Weil KM, Hernandez TL, and Eckel RH. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 23: 307-313, 2003.
5. Cernuda-Morollon E, Rodriguez-Pascual F, Klatt P, Lamas S, and Perez-Sala D. PPARα agonists amplify iNOS expression while inhibiting NFB: implications for mesangial cell activation by cytokines. Am Soc Nephrol 13: 2223-2231, 2002.
6. Cowart AL, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, and Capdevila JH. The CYP 4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity PPAR ligands. J Biol Chem 277: 35105-35112, 2002.
7. Despres JP, Lemieux I, Salomon H, and Delaval D. Effects of micronized fenofibrate versus atrovastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 251: 490-499, 2002.
8. Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, and Imig JD. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res 12: 1278-1289, 2004.
9. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
10. Frisbee JC. Impaired dilation of skeletal muscle microvessels to reduced oxygen tension in diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1568-H1574, 2001.
11. Frisbee JC and Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol 281: H1304-H1311, 2001.
12. Fruchart JC, Duriez P, and Staels B. Molecular mechanism of action of the fibrates. J Soc Biol 193: 67-75, 1999.
13. Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T, Takata Y, and Fujishima M. Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res 70: 660-669, 1992.
14. Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K, and Shimamoto K. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 174: 321-329, 2002.
15. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, and Staels B. Peroxisome proliferator-activated receptor-α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000.
16. Haak T, Haak E, Kusterer K, Weber A, Kohleisen M, and Usadel KH. Fenofibrate improves microcirculation in patients with hyperlipidemia. Eur J Med Res 3: 50-54, 1998.
17. Hayashi K, Kanda T, Homma K, Tokuyama H, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, and Saruta T. Altered renal microvascular response in Zucker obese rats. Metabolism 51: 1553-1561, 2002.
18. Holla VR, Makita K, Zaphiropoulos PG, and Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 104: 751-760, 1999.
19. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 279: F965-F981, 2000.
20. Imig JD, Navar LG, Roman RJ, Reddy KK, and Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996.
21. Imig JD, Zhao X, Falck JR, Wei S, and Capdevila JH. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonamide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens 19: 983-1092, 2001.
22. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, and Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132, 2003.
23. Jin JS and Bohlen HG. Non-insulin-dependent diabetes and hyperglycemia impair rat intestinal flow-mediated regulation. Am J Physiol Heart Circ Physiol 272: H728-H734, 1997.
24. Kagota S, Tamashiro A, Yamaguchi Y, Nakamura K, and Kunitomo M. Excessive salt or cholesterol intake alters the balance among endothelium-derived factors released form renal arteries in spontaneously hypertensive rats. J Cardiovasc Pharmacol 34: 533-539, 1999.
25. Liang B, McMaster JC, Kroeger EA, Hatch GM, Mymin D, Dembinski T, Arthur G, Shen G, Man RY, and Choy PC. The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients. Mol Cell Biochem 207: 123-129, 2000.
26. Makino A, Ohuchi K, and Kamata K. Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br J Pharmacol 130: 549-556, 2000.
27. McLenachan JM, Vita J, Fish DR, Teasure CB, Cos DA, Ganz P, and Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branching points. Circulation 82: 1169-1173, 1990.
28. Miyoshi A, Suzuki M, Masai M, and Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am J Hypertens 10: 1083-1090, 1997.
29. Muller DN, Theuer J, Shagdarsuren E, Kaergel E, Honeck H, Park JK, Markovic M, Barbosa-Sicard E, Dechend R, Wellner M, Kirsch T, Fiebeler A, Rothe M, Haller H, Luft FC, and Schunck WH. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164: 521-532, 2004.
30. Naderali EK, Fatani S, and Williams G. Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats. Atherosclerosis 177: 307-312, 2004.
31. Nasrallah R and Hebert RL. Prostacyclin signaling in the kidney: implication for health and disease. Am J Physiol Renal Physiol 289: F235-F246, 2005.
32. + transport in the rat. BMC Pharmacol 4: 1, 2004 (EPub 6 February 2004).
33. Newaz M, Blanton A, Fidelis P, and Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferators activated receptor (PPAR)α-mediated cardiovascular effects. Mutat Res 579: 163-171, 2005.
34. Playford DA, Watts GF, Best JD, and Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 90: 1254-1257, 2002.
35. Rahman M, Wright JT Jr, and Douglas JG. The role of the cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: a review. Am J Hypertens 10: 356 -365, 1997.
36. Staels B, Wolfgang K, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393: 790-793, 1998.
37. Steiner G. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes. Lancet 357: 905-910, 2001.
38. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, Mishal Z, Zoria J, Li H, and Soria C. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 60: 810-819, 2003.
39. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, and Dorrance AM. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 42: 594-599, 2003.
40. Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, and Schwartzman ML. Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11, 12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 336: 240-250, 1996.
41. Wang PR, Guo Q, and Ippolito M. High fat fed hamster, a unique animal model for treatment of diabetic dyslipideamia with peroxisome proliferator activated receptor-α-selective agonists. Eur J Pharmacol 427: 285-293, 2001.
42. Wigg SJ, Tare M, Tonta MA, O'Brien RC, Meredith IT, and Parkington HC. Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am J Physiol Heart Circ Physiol 281: H232-H240, 2001.
43. Wolin MS. Reactive oxygen species and vascular signal transduction mechanisms. Microcirculation 3: 1-17, 1996.
44. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, and Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 57: 1011-1020, 2000.
45. Zanchi A, Delacretaz E, Taleb V, Gaillard R, Jeanrenaud B, Brunner HR, and Waeber B. Endothelial function of the mesenteric arteriole and mechanical behavior of the carotid artery in rats with insulin resistance and hypercholesterolemia. J Hypertens 13: 1463-1470, 1995.
46. Zeiher AM, Drexler H, Wollschläger H, and Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 84: 1984-1992, 1991.
47. Zeiher AM, Drexler H, Wollschläger H, and Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83: 391-401, 1991.
48. Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, and Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 288: R188-R196, 2005.
49. Zhao X, Inscho EW, Bondlela M, Falck JR, and Imig JD. The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. Am J Physiol Heart Circ Physiol 281: H2089-H2096, 2001.
50. Zhao X, Pollock DM, Inscho EW, Zeldin DC, and Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension 41: 709-714, 2003.